CHEMOCENTRYX INC (CCXI)

US16383L1061 - Common Stock

51.99  +0.03 (+0.06%)

After market: 51.99 0 (0%)

Fundamental Rating

3

Overall CCXI gets a fundamental rating of 3 out of 10. We evaluated CCXI against 592 industry peers in the Biotechnology industry. Both the profitability and financial health of CCXI have multiple concerns. CCXI shows excellent growth, but is valued quite expensive already.



0

1. Profitability

1.1 Basic Checks

CCXI had negative earnings in the past year.
In the past year CCXI has reported a negative cash flow from operations.
CCXI had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CCXI reported negative operating cash flow in multiple years.

1.2 Ratios

Industry RankSector Rank
ROA -31.74%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -353.17%
PM (TTM) -357.01%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

CCXI does not have a ROIC to compare to the WACC, probably because it is not profitable.
CCXI has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, CCXI has a worse debt to assets ratio.

2.2 Solvency

An Altman-Z score of 9.70 indicates that CCXI is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of 0.02 indicates that CCXI is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 9.7
ROIC/WACCN/A
WACC9.62%

2.3 Liquidity

CCXI has a Current Ratio of 4.54. This indicates that CCXI is financially healthy and has no problem in meeting its short term obligations.
CCXI has a Quick Ratio of 4.47. This indicates that CCXI is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.54
Quick Ratio 4.47

7

3. Growth

3.1 Past

CCXI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.78%.
Looking at the last year, CCXI shows a very strong growth in Revenue. The Revenue has grown by 72.49%.
Measured over the past years, CCXI shows a very strong growth in Revenue. The Revenue has been growing by 21.96% on average per year.
EPS 1Y (TTM)-6.78%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q21.43%
Revenue 1Y (TTM)72.49%
Revenue growth 3Y-9.08%
Revenue growth 5Y21.96%
Revenue growth Q2Q548.81%

3.2 Future

CCXI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.34% yearly.
CCXI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 134.59% yearly.
EPS Next Y9.69%
EPS Next 2Y37.13%
EPS Next 3Y41.06%
EPS Next 5Y47.34%
Revenue Next Year117.77%
Revenue Next 2Y157.52%
Revenue Next 3Y130.02%
Revenue Next 5Y134.59%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

CCXI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CCXI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -26.68

4.3 Compensation for Growth

CCXI's earnings are expected to grow with 41.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.13%
EPS Next 3Y41.06%

0

5. Dividend

5.1 Amount

CCXI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CHEMOCENTRYX INC

NASDAQ:CCXI (10/19/2022, 7:04:24 PM)

After market: 51.99 0 (0%)

51.99

+0.03 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.71B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.74%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -353.17%
PM (TTM) -357.01%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.54
Quick Ratio 4.47
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-6.78%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y9.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)72.49%
Revenue growth 3Y-9.08%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y